Medications for Stimulant Use Disorder: What Is Approved?

Medications for stimulant use disorder can be considered in some treatment plans, even though none has an FDA-approved indication for treating the disorder. The distinction is between approval for a specific use and a clinician’s decision to consider an off-label option. Behavioral treatment remains central. The ASAM/AAAP guideline explains both points.

Hearing “there is no approved medicine” can sound like medication has no possible role. Hearing that a guideline discusses medication can sound like a standard prescription is available for everyone. Neither conclusion is accurate. The American Society of Addiction Medicine and American Academy of Addiction Psychiatry’s 2024 guideline allows selected off-label medication consideration while describing important limits in the evidence. It also recommends treating co-occurring conditions alongside stimulant use disorder. Understanding what a medicine is intended to treat helps separate these decisions without turning a general treatment article into a personal prescribing recommendation.

How does an approved indication differ from off-label use?

An approved indication is a condition a medicine has FDA approval to treat; off-label use means using a medicine outside its approved indication. For stimulant use disorder, the ASAM/AAAP guideline reports no FDA-approved medication, while allowing certain off-label considerations. This distinction fits within a broader plan that may include contingency management for stimulant use disorder and care for substance use alongside mental health and trauma.

Approval belongs to a particular use, rather than being a general endorsement for every condition. A medicine’s approval for depression, ADHD, or another disorder does not establish approval for treating stimulant use disorder. Conversely, the absence of that specific approval does not mean a clinician can never consider the medicine for that purpose.

The guideline makes this distinction explicit. Its authors acknowledge that medication evidence for stimulant use disorder is relatively limited, but conclude that some options may help selected patients, especially when other conditions are present. That is a qualified clinical judgment, not a promise of benefit or a recommendation that everyone should receive medication. See the guideline’s pharmacotherapy discussion.

These distinctions reflect the guideline’s separate recommendations for ongoing stimulant treatment, co-occurring disorders, and acute intoxication or withdrawal. Source: ASAM/AAAP Clinical Practice Guideline.

What does the stimulant guideline say about medication?

The guideline says clinicians can consider certain medications off-label, with recommendations that depend on the stimulant involved and the person’s circumstances. This adds detail to general information about substance-use care; it does not mean every outpatient treatment program offers those medications. The recommendations and their evidence ratings appear in the guideline’s pharmacotherapy section.

The wording “can consider” matters. Many medication recommendations are conditional, meaning they call for a decision based on the situation rather than routine use for everyone. Evidence certainty is a separate issue: a low-certainty rating signals more uncertainty about the estimated effects than a higher-certainty rating. A guideline mention therefore needs to be read with its limits.

Examples show why there is no single medication rule for all stimulant use disorders:

• Bupropion: The guideline conditionally supports consideration for cocaine use disorder, with low-certainty evidence. Its recommendation for amphetamine-type stimulant use disorder is more limited and concerns lower-frequency use.
• Bupropion with naltrexone: The combination receives a conditional recommendation for amphetamine-type stimulant use disorder, with moderate-certainty evidence. Evidence for a combination does not establish that either medicine alone has the same effect.
• Topiramate: The guideline allows consideration for cocaine or amphetamine-type stimulant use disorder, with low-certainty evidence. Its discussion describes mixed findings for cocaine-related outcomes.

These are examples of the guideline’s reasoning, not a list of medicines to try. They are not interchangeable, and evidence about cocaine cannot automatically be applied to methamphetamine or another stimulant. Recommendations 9–14 describe these distinctions.

Naltrexone also illustrates why a familiar medicine name is not enough to guide a decision. It can cause or worsen opioid withdrawal in someone with recent opioid exposure. That requires a prescriber’s safety assessment, including consideration of other substances and medications. MedlinePlus explains naltrexone’s precautions. No general article can establish that a particular option is safe for one reader.

Why does behavioral treatment remain central?

Behavioral treatment remains central because its role is supported independently of any medication decision. The guideline identifies contingency management as the current standard of care for stimulant use disorder. Work on personal triggers and response patterns addresses another practical part of treatment. The guideline recommends contingency management as a primary treatment component.

Contingency management uses tangible reinforcement for specific, measurable treatment behaviors or goals. The guideline recommends it alongside other psychosocial treatments, which are treatments focused on behavior, coping, relationships, and daily life. Cognitive behavioral therapy, the community reinforcement approach, and the Matrix Model have supporting evidence as companion approaches. This is general treatment evidence, not confirmation that every approach is offered at Women’s Recovery.

Behavioral treatment and medication also address different parts of care. A medication decision does not replace learning how to respond to a cue, handle stress, or remain engaged with treatment. NIDA describes behavioral therapies as ways to help people change substance-related attitudes and behaviors and cope with situations linked to a return to use. NIDA’s treatment and recovery overview explains these roles.

This resolves the apparent conflict between sources. NIDA’s general overview emphasizes behavioral treatment for stimulant addiction. The later ASAM/AAAP guideline discusses selected off-label medication possibilities while keeping behavioral care at the center. Off-label consideration expands an individualized plan; it does not establish a medication-first approach for everyone.

How can co-occurring conditions influence prescribing?

Another condition can change the purpose, potential benefit, and risks of a medication decision. Co-occurring care addresses concerns together, and Women’s Recovery’s substance-use care model includes mental health and trauma. The stimulant guideline recommends treating co-occurring psychiatric disorders and other substance use disorders concurrently, with care coordination. See recommendations 21–25.

The target of treatment needs to stay clear. A medicine prescribed for depression may be intended to improve depression. A medicine prescribed for ADHD may be intended to improve attention-related symptoms and functioning. Neither purpose should be described automatically as medication treatment for stimulant use disorder. In some cases, a clinician may consider potential effects on both conditions, but each goal still needs its own review.

The guideline gives some medications additional consideration when a relevant co-occurring condition is present. For example, some recommendations discuss depression, tobacco use disorder, or alcohol use disorder as factors that may affect the choice. Those details help explain why two people with the same stimulant-use diagnosis might receive different recommendations. The medication-specific recommendations identify these factors.

ADHD deserves particular care in this discussion. A stimulant use disorder does not automatically rule out ADHD treatment. The guideline supports addressing ADHD symptoms and weighing the benefits and risks of stimulant medication, nonstimulant medication, and behavioral approaches. That does not authorize self-treatment or the use of another person’s prescription. It calls for an individual clinical decision. Recommendations 26–28 address ADHD and stimulant use disorder.

Symptoms also need context. Depression, anxiety, sleep problems, and attention difficulties can occur during different phases of stimulant use or withdrawal. The guideline advises clinicians to consider their timing, severity, and duration rather than assuming one cause. Care can address distress while that fuller assessment continues.

Why do specialist expertise and monitoring matter?

Medication consideration requires relevant expertise and follow-up, even when outpatient treatment otherwise fits a person’s needs. Case management and care coordination serve a different role from a prescriber’s safety assessment. For psychostimulants prescribed specifically to treat stimulant use disorder, the guideline sets particular expectations for physician expertise and close monitoring. Its psychostimulant recommendations explain these safeguards.

The guideline limits this prescribing to physicians board certified in addiction medicine or addiction psychiatry, or physicians with comparable training, competence, and capacity for close monitoring. This is narrower than saying any clinician should prescribe a stimulant because a guideline lists it. Treating ADHD and prescribing a psychostimulant specifically for stimulant use disorder are also distinct decisions.

Monitoring is part of evaluating whether the plan remains appropriate. Depending on the medicine and individual risks, the guideline describes:

• Benefit review: Reassessing the intended treatment goals and whether meaningful improvement is occurring.
• Physical safety review: Considering cardiovascular health and monitoring relevant effects when psychostimulants are prescribed.
• Medication-use review: Using measures such as prescription-monitoring database checks, pill counts, or drug testing when appropriate.
• Psychiatric review: Considering psychosis, mood symptoms, and other concerns that may change the risk-benefit balance.

These measures should follow the medicine’s risks and the person’s circumstances, rather than a universal checklist. The guideline also advises generally avoiding certain options in people with a history of psychosis. See the psychostimulant monitoring and safety discussion.

Does a program description confirm a specific medication?

No. Women’s Recovery’s outpatient program description and substance-use care description do not establish availability of a particular off-label stimulant-use medication. A statement about psychiatric care cannot be expanded into a claim that a named medicine, combination, or specialist prescribing service is offered.

Women’s Recovery provides outpatient mental health, trauma, and substance-use programs in Denver, CO, including a Partial Hospitalization Program (PHP) and an Intensive Outpatient Program (IOP). It does not provide onsite detox, residential treatment, or inpatient care. A medication mentioned in a national guideline does not change those service limits.

For someone considering care, the useful distinction is between evidence about a treatment option and confirmation of an individual treatment plan. The evidence can explain why medication might be considered. It cannot establish who will prescribe it, where it is available, or whether it fits a person’s health needs.

You can contact Women’s Recovery or call 833.754.0554 to discuss current outpatient options. You do not need to select a medicine or choose a program before reaching out.

Frequently asked questions